Kyra A Gelderman Selected Research

neutrophil cytosolic factor 1

7/2009	Ncf1-associated reduced oxidative burst promotes IL-33R+ T cell-mediated adjuvant-free arthritis in mice.
10/2007	Macrophages suppress T cell responses and arthritis development in mice by producing reactive oxygen species.
8/2006	T cell surface redox levels determine T cell reactivity and arthritis susceptibility.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kyra A Gelderman Research Topics

Disease

7	Arthritis (Polyarthritis) 02/2011 - 08/2006
6	Neoplasms (Cancer) 04/2006 - 01/2002
4	Infections 12/2021 - 01/2018
4	Inflammation (Inflammations) 01/2020 - 09/2006
3	Colorectal Neoplasms (Colorectal Cancer) 04/2006 - 01/2002
2	Tuberculosis (Tuberculoses) 01/2020 - 01/2018
2	Lung Diseases (Lung Disease) 01/2020 - 01/2018
2	Celiac Disease (Celiac Sprue) 06/2014 - 04/2013
2	Rheumatoid Arthritis 10/2007 - 09/2006
2	Autoimmune Diseases (Autoimmune Disease) 10/2007 - 10/2007
2	Neoplasm Metastasis (Metastasis) 06/2004 - 05/2004
1	Myositis (Idiopathic Inflammatory Myopathies) 01/2020
1	Dermatomyositis (Dermatopolymyositis) 01/2020
1	Paraproteinemias (Monoclonal Gammopathy) 01/2018
1	Atypical Hemolytic Uremic Syndrome 01/2018
1	Ulcerative Colitis 06/2014
1	Crohn Disease (Crohn's Disease) 06/2014
1	Atrophy 01/2013
1	Experimental Arthritis 10/2007
1	Necrosis 09/2006
1	Renal Cell Carcinoma (Grawitz Tumor) 05/2004
1	Neoplasm Micrometastasis 05/2004
1	Carcinoma (Carcinomatosis) 04/2002

Drug/Important Bio-Agent (IBA)

10	Complement System Proteins (Complement)IBA 01/2020 - 01/2002
7	AntigensIBA 12/2021 - 04/2002
6	Proteins (Proteins, Gene)FDA Link 01/2018 - 01/2002
6	Reactive Oxygen Species (Oxygen Radicals)IBA 02/2011 - 08/2006
3	Biomarkers (Surrogate Marker)IBA 01/2020 - 01/2018
3	AntibodiesIBA 01/2020 - 04/2006
3	neutrophil cytosolic factor 1IBA 07/2009 - 08/2006
3	Collagen Type II (Type II Collagen)IBA 07/2009 - 08/2007
3	Epithelial Cell Adhesion MoleculeIBA 04/2006 - 01/2002
3	Monoclonal AntibodiesIBA 12/2005 - 04/2002
2	Immunoglobulins (Immunoglobulin)IBA 12/2021 - 01/2018
2	NADPH Oxidases (NAD(P)H oxidase)IBA 10/2007 - 08/2007
2	beta-GlucansIBA 04/2006 - 05/2004
2	Bispecific AntibodiesIBA 06/2004 - 04/2002
1	C-Reactive ProteinIBA 12/2021
1	Complement C1 Inhibitor Protein (C1 Esterase Inhibitor)IBA 01/2020
1	N 30IBA 01/2020
1	Immunoglobulin A (IgA)IBA 06/2014
1	Oxidoreductases (Dehydrogenase)IBA 10/2010
1	AutoantibodiesIBA 07/2009
1	AutoantigensIBA 07/2009
1	CollagenIBA 10/2007
1	4- ethoxymethylene- 2- phenyl- 2- oxazoline- 5- one (phOx)IBA 08/2007
1	Histocompatibility Antigens Class IIIBA 08/2007
1	Oxygen (Dioxygen)IBA 08/2007
1	EpitopesIBA 08/2007
1	PhytolIBA 09/2006
1	Methotrexate (Mexate)FDA LinkGeneric 09/2006
1	Biological ProductsIBA 09/2006
1	Glutathione (Reduced Glutathione)IBA 08/2006
1	Sulfhydryl Compounds (Thiols)IBA 08/2006
1	Complement C3b (C3bi)IBA 04/2006
1	Neoplasm Antigens (Tumor Antigens)IBA 04/2006
1	cobra venom factorIBA 06/2004
1	G250 monoclonal antibodyIBA 05/2004
1	SuspensionsIBA 04/2002
1	Complement Membrane Attack Complex (Membrane Attack Complex)IBA 04/2002

Therapy/Procedure

5	Immunotherapy 04/2006 - 01/2002
3	Gluten-Free Diet 06/2014 - 01/2013
2	Therapeutics 01/2018 - 09/2006
1	Drug Therapy (Chemotherapy) 05/2004